These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24463160)

  • 1. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
    Mehta DA; Hay JW
    Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
    Lesnock JL; Farris C; Krivak TC; Smith KJ; Markman M
    Gynecol Oncol; 2011 Sep; 122(3):473-8. PubMed ID: 21665250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
    Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
    Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
    Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
    Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
    Cohn DE; Barnett JC; Wenzel L; Monk BJ; Burger RA; Straughn JM; Myers ER; Havrilesky LJ
    Gynecol Oncol; 2015 Feb; 136(2):293-9. PubMed ID: 25449568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Seagle BL; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):9-14. PubMed ID: 28196674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
    Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
    Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
    Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
    Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
    Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
    Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
    Chan JK; Herzog TJ; Hu L; Monk BJ; Kiet T; Blansit K; Kapp DS; Yu X
    Oncologist; 2014 May; 19(5):523-7. PubMed ID: 24721817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
    Goulart B; Ramsey S
    Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
    Peng J; Xu H; Liu Q
    PLoS One; 2024; 19(10):e0312133. PubMed ID: 39423210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
    Neyt M; Vlayen J; Devriese S; Camberlin C
    PLoS One; 2018; 13(4):e0195134. PubMed ID: 29630612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.